Neoleukin Therapeutics, Inc. (NLTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NLTX Stock Price Chart Interactive Chart >
NLTX Price/Volume Stats
| Current price | $1.00 | 52-week high | $11.10 |
| Prev. close | $1.02 | 52-week low | $0.92 |
| Day low | $0.96 | Volume | 196,800 |
| Day high | $1.03 | Avg. volume | 263,320 |
| 50-day MA | $1.44 | Dividend yield | N/A |
| 200-day MA | $4.37 | Market Cap | 42.50M |
Neoleukin Therapeutics, Inc. (NLTX) Company Bio
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops medicines to treat serious diseases, including cancer, inflammatory, and autoimmune disorders.
Latest NLTX News From Around the Web
Below are the latest news stories about Neoleukin Therapeutics Inc that investors may wish to consider to help them evaluate NLTX as an investment opportunity.
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced , today announced it will report full year 2021 financial results on Tuesday, March 1, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as f |
Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cytokinetics (CYTK) and Neoleukin Therapeutics (NLTX)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report), Cytokinetics (CYTK – Research Report) and Neoleukin Therapeutics (NLTX – Research Report). Boston Scientific (BSX) In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific. The company's shares closed last Tuesday at $43.84. According to TipRanks. |
Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology ConferenceSEATTLE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Oncology Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 1:30 p.m. Eastern. The webcast presentation can be accessed from the investo |
As Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) drops to US$138m market cap, insiders might rethink their US$1.4m stock purchase earlier this yearThe recent 15% drop in Neoleukin Therapeutics, Inc.'s ( NASDAQ:NLTX ) stock could come as a blow to insiders who... |
Wall Street Analysts Are Bullish on Top Healthcare PicksThere's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neoleukin Therapeutics (NLTX – Research Report), Sarepta Therapeutics (SRPT – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments. Neoleukin Therapeutics (NLTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Neoleukin Therapeutics, with a price target of $22.00. The company's shares closed last Monday at $4.20. According to TipRanks. |
NLTX Price Returns
| 1-mo | -20.00% |
| 3-mo | -62.96% |
| 6-mo | -80.43% |
| 1-year | -90.00% |
| 3-year | -61.83% |
| 5-year | -92.70% |
| YTD | -79.25% |
| 2021 | -65.82% |
| 2020 | 14.45% |
| 2019 | 470.37% |
| 2018 | -81.63% |
| 2017 | -28.77% |
Loading social stream, please wait...